Your browser doesn't support javascript.
loading
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang, Yemin; Chen, Shary Yuting; Karnezis, Anthony N; Colborne, Shane; Santos, Nancy Dos; Lang, Jessica D; Hendricks, William Pd; Orlando, Krystal A; Yap, Damian; Kommoss, Friedrich; Bally, Marcel B; Morin, Gregg B; Trent, Jeffrey M; Weissman, Bernard E; Huntsman, David G.
Afiliação
  • Wang Y; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Chen SY; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Karnezis AN; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Colborne S; Michael Smith Genome Science Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Santos ND; Department of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Lang JD; Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA.
  • Hendricks WP; Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA.
  • Orlando KA; Department of Pathology and Laboratory Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Yap D; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Kommoss F; Department of Pathology and Laboratory Medicine, University of British Columbia and Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Bally MB; Department of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Morin GB; Department of Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Trent JM; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
  • Weissman BE; Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA.
  • Huntsman DG; Department of Pathology and Laboratory Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
J Pathol ; 242(3): 371-383, 2017 07.
Article em En | MEDLINE | ID: mdl-28444909
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Histona-Lisina N-Metiltransferase / Carcinoma de Células Pequenas / Proteína Potenciadora do Homólogo 2 de Zeste / Hipercalcemia Limite: Animals / Female / Humans Idioma: En Revista: J Pathol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Histona-Lisina N-Metiltransferase / Carcinoma de Células Pequenas / Proteína Potenciadora do Homólogo 2 de Zeste / Hipercalcemia Limite: Animals / Female / Humans Idioma: En Revista: J Pathol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Canadá